{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:41:47Z","timestamp":1791988907112,"version":"4.4.0"},"reference-count":270,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"DOI":"10.3389\/fcell.2020.569219","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T05:05:37Z","timestamp":1602738337000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":95,"title":["Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies"],"prefix":"10.3389","volume":"8","author":[{"given":"Kaijian","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.critrevonc.2019.08.009","article-title":"The clinical significance of soluble PD-1 and PD-L1 in lung cancer.","volume":"143","author":"Abu Hejleh","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2217\/imt-2016-0150","article-title":"PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.","volume":"9","author":"Aguiar","year":"2017","journal-title":"Immunotherapy"},{"key":"B3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/intimm\/dxz060","article-title":"Matrix metalloproteinases cleave membrane-bound PD-L1 on CD90+ (myo-)fibroblasts in Crohn\u2019s disease and regulate Th1\/Th17 cell responses.","volume":"32","author":"Aguirre","year":"2020","journal-title":"Int. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4749","DOI":"10.1073\/pnas.1718217115","article-title":"Role of PD-1 during effector CD8 T cell differentiation.","volume":"115","author":"Ahn","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","article-title":"Roles of PD-1\/PD-L1 Pathway: signaling. Cancer, and Beyond.","volume":"1248","author":"Ai","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome.","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1126\/science.aaa4024","article-title":"Cancer. Malicious exosomes.","volume":"346","author":"Anastasiadou","year":"2014","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation.","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"B10","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.21873\/anticanres.13716","article-title":"Plasma Levels of Soluble PD-L1 correlate with tumor regression in patients with lung and gastric cancer treated with immune checkpoint inhibitors.","volume":"39","author":"Ando","year":"2019","journal-title":"Anticancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","article-title":"Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups.","volume":"20","author":"Andrews","year":"2019","journal-title":"Nat. Immunol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65895-0","article-title":"Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas.","volume":"10","author":"Asanuma","year":"2020","journal-title":"Sci. Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/ncb2502","article-title":"Syndecan-syntenin-ALIX regulates the biogenesis of exosomes.","volume":"14","author":"Baietti","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis.","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.21873\/anticanres.12662","article-title":"Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.","volume":"38","author":"Bassanelli","year":"2018","journal-title":"Anticancer Res."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117437","article-title":"PD-L1\/PD-1 axis as a potent therapeutic target in breast cancer.","volume":"247","author":"Bastaki","year":"2020","journal-title":"Life Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.tcb.2013.10.009","article-title":"ALIX and the multivesicular endosome: ALIX in Wonderland.","volume":"24","author":"Bissig","year":"2014","journal-title":"Trends Cell Biol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-57497-7","article-title":"A comparison of methods for the isolation and separation of extracellular vesicles from protein and lipid particles in human serum.","volume":"10","author":"Brennan","year":"2020","journal-title":"Sci. Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.lungcan.2017.08.005","article-title":"PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.","volume":"112","author":"Brody","year":"2017","journal-title":"Lung Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01015","article-title":"Soluble programmed death receptor ligands sPD-L1 and sPD-L2 as liquid biopsy markers for prognosis and platinum response in epithelial ovarian cancer.","volume":"9","author":"Buderath","year":"2019","journal-title":"Front. Oncol."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01474","article-title":"Biomarkers for clinical benefit of immune checkpoint inhibitor treatment-A review from the melanoma perspective and beyond.","volume":"9","author":"Buder-Bakhaya","year":"2018","journal-title":"Front. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1016\/j.molimm.2008.05.014","article-title":"Interaction of human PD-L1 and B7-1.","volume":"45","author":"Butte","year":"2008","journal-title":"Mol. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1042\/BST0381397","article-title":"The ESCRT machinery: a cellular apparatus for sorting and scission.","volume":"38","author":"Carlton","year":"2010","journal-title":"Biochem. Soc. Trans."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01288","article-title":"Immunomodulatory effect of MSC on B cells is independent of secreted extracellular vesicles.","volume":"10","author":"Carreras-Planella","year":"2019","journal-title":"Front. Immunol."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2019.1703244","article-title":"Inhibiting extracellular vesicles formation and release: a review of EV inhibitors.","volume":"9","author":"Catalano","year":"2020","journal-title":"J. Extracell. Vesicles"},{"key":"B27","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms Controlling PD-L1 expression in cancer.","volume":"76","author":"Cha","year":"2019","journal-title":"Mol. Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1007\/s10147-019-01588-7","article-title":"Current issues and perspectives in PD-1 blockade cancer immunotherapy.","volume":"25","author":"Chamoto","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00262-018-2271-4","article-title":"The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.","volume":"68","author":"Chang","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1158\/1078-0432.CCR-16-2366","article-title":"Clinical use of programmed cell death-1 and its ligand expression as discriminatory and predictive markers in ovarian cancer.","volume":"23","author":"Chatterjee","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1158\/2326-6066.CIR-17-0316","article-title":"PD-L1 Binds to B7-1 only in Cis on the same cell surface.","volume":"6","author":"Chaudhri","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation.","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition.","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5364-3","article-title":"Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells.","volume":"19","author":"Chen","year":"2019","journal-title":"BMC Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/JTO.0000000000000500","article-title":"Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-Driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation.","volume":"10","author":"Chen","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.ijbiomac.2018.02.034","article-title":"Poly(I:C) enhanced anti-cervical cancer immunities induced by dendritic cells-derived exosomes.","volume":"113","author":"Chen","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"11771","DOI":"10.1074\/jbc.M112.448126","article-title":"Structure and interactions of the human programmed cell death 1 receptor.","volume":"288","author":"Cheng","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.tips.2015.06.005","article-title":"New immunotherapies targeting the PD-1 pathway.","volume":"36","author":"Chinai","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1177\/0003489419896602","article-title":"Abscopal effect following immunotherapy and combined stereotactic body radiation therapy in recurrent metastatic head and neck squamous cell carcinoma: a report of two cases and literature review.","volume":"129","author":"Choi","year":"2020","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"8977","DOI":"10.1021\/acsnano.8b02446","article-title":"M1 macrophage-derived nanovesicles potentiate the anticancer efficacy of immune checkpoint inhibitors.","volume":"12","author":"Choo","year":"2018","journal-title":"ACS Nano"},{"key":"B42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.tibs.2016.08.016","article-title":"Cellular functions and molecular mechanisms of the ESCRT membrane-scission machinery.","volume":"42","author":"Christ","year":"2017","journal-title":"Trends Biochem. Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.humpath.2015.09.003","article-title":"PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.","volume":"47","author":"Cimino-Mathews","year":"2016","journal-title":"Hum. Pathol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-cellbio-101512-122326","article-title":"Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles.","volume":"30","author":"Colombo","year":"2014","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2019.1710899","article-title":"Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients.","volume":"9","author":"Cordonnier","year":"2020","journal-title":"J. Extracell. Vesicles"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1452581","article-title":"Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab.","volume":"7","author":"Costantini","year":"2018","journal-title":"Oncoimmunology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy.","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1080\/14737159.2020.1688144","article-title":"Beyond tumor mutational burden: potential and limitations in using exosomes to predict response to immunotherapy.","volume":"19","author":"Crow","year":"2019","journal-title":"Expert Rev. Mol. Diagn."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature.","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10979-3","article-title":"Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma.","volume":"10","author":"Czystowska-Kuzmicz","year":"2019","journal-title":"Nat. Commun."},{"key":"B51","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-019-0264-y","article-title":"The importance of exosomal PDL1 in tumour immune evasion.","volume":"20","author":"Daassi","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cellimm.2014.05.006","article-title":"The PD-1\/PD-Ls pathway and autoimmune diseases.","volume":"290","author":"Dai","year":"2014","journal-title":"Cell. Immunol."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.","volume":"7","author":"Davis","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/bjc.2018.9","article-title":"PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC.","volume":"118","author":"Del Re","year":"2018","journal-title":"Br. J. Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20200042","article-title":"The abscopal effect 67 years later: from a side story to center stage.","volume":"93","author":"Demaria","year":"2020","journal-title":"Br. J. Radiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.","volume":"124","author":"Deng","year":"2014","journal-title":"J. Clin. Invest."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1091146","article-title":"A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage.","volume":"5","author":"Dezutter-Dambuyant","year":"2016","journal-title":"Oncoimmunology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.neurobiolaging.2014.02.012","article-title":"Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer\u2019s disease.","volume":"35","author":"Dinkins","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"B59","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.","volume":"5","author":"Dong","year":"1999","journal-title":"Nat. Med."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136133","article-title":"Characterization of RNA from exosomes and other extracellular vesicles isolated by a novel spin column-based method.","volume":"10","author":"Enderle","year":"2015","journal-title":"PLoS One"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1245\/s10434-019-07431-7","article-title":"Exosomal PD-L1 retains immunosuppressive activity and is associated with gastric cancer prognosis.","volume":"26","author":"Fan","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-019-0735-3","article-title":"Advances on immune-related adverse events associated with immune checkpoint inhibitors.","author":"Fan","year":"2020","journal-title":"Front. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.biotechadv.2017.12.010","article-title":"Exosome biogenesis, bioactivities and functions as new delivery systems of natural compounds.","volume":"36","author":"Farooqi","year":"2018","journal-title":"Biotechnol. Adv."},{"key":"B65","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40265-016-0588-x","article-title":"Cancer treatment with Anti-PD-1\/PD-L1 agents: Is PD-L1 expression a biomarker for patient selection?","volume":"76","author":"Festino","year":"2016","journal-title":"Drugs"},{"key":"B66","doi-asserted-by":"publisher","first-page":"773","DOI":"10.26355\/eurrev_202001_20058","article-title":"Abscopal effect and interventional oncology: state of art and future perspectives.","volume":"24","author":"Fionda","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B67","first-page":"3325","article-title":"Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.","volume":"57","author":"Foster","year":"1997","journal-title":"Cancer Res."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65915-z","article-title":"GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors.","volume":"10","author":"Fu","year":"2020","journal-title":"Sci. Rep."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1002\/art.40164","article-title":"Contribution of soluble forms of programmed death 1 and programmed death ligand 2 to disease severity and progression in systemic sclerosis.","volume":"69","author":"Fukasawa","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcdb.2017.11.003","article-title":"The ESCRT machinery: When function follows form.","volume":"74","author":"Furthauer","year":"2018","journal-title":"Semin. Cell Dev. Biol."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06755-y","article-title":"PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.","volume":"20","author":"Furuse","year":"2020","journal-title":"BMC Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2020.06.016","article-title":"Severe immune-related hepatitis induced by immune checkpoint inhibitors: clinical features and management proposal.","author":"Gauci","year":"2020","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"B74","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/PPO.0000000000000176","article-title":"Immune checkpoint therapies in prostate cancer.","volume":"22","author":"Goswami","year":"2016","journal-title":"Cancer J."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3402\/jev.v2i0.20389","article-title":"As we wait: coping with an imperfect nomenclature for extracellular vesicles.","volume":"2","author":"Gould","year":"2013","journal-title":"J. Extracell. Vesicles"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02100","article-title":"The antitumor activity of combinations of cytotoxic chemotherapy and immune checkpoint inhibitors is model-dependent.","volume":"9","author":"Grasselly","year":"2018","journal-title":"Front. Immunol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"286","DOI":"10.21037\/tlcr.2019.04.14","article-title":"Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey.","volume":"8","author":"Gregg","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00281-018-0681-1","article-title":"The role of extracellular vesicles when innate meets adaptive.","volume":"40","author":"Groot Kormelink","year":"2018","journal-title":"Semin. Immunopathol."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0449-0","article-title":"Soluble immune checkpoints in cancer: production, function and biological significance.","volume":"6","author":"Gu","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.apsb.2016.02.001","article-title":"Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges.","volume":"6","author":"Ha","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"B81","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer.","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-020-00455-7","article-title":"Exosomal cargos modulate autophagy in recipient cells via different signaling pathways.","volume":"10","author":"Hassanpour","year":"2020","journal-title":"Cell Biosci."},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133501","article-title":"Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy.","volume":"5","author":"Hatae","year":"2020","journal-title":"JCI Insight"},{"key":"B84","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/abbs\/36.4.284","article-title":"Cloning and identification of two novel splice variants of human PD-L2.","volume":"36","author":"He","year":"2004","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"B85","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.devcel.2011.05.015","article-title":"The ESCRT pathway.","volume":"21","author":"Henne","year":"2011","journal-title":"Dev. Cell"},{"key":"B86","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1002\/jcb.26364","article-title":"Tumor-derived exosomes: potential biomarker or therapeutic target in breast cancer?","volume":"119","author":"Hesari","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"B87","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00018-017-2595-9","article-title":"Current knowledge on exosome biogenesis and release.","volume":"75","author":"Hessvik","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3892\/ijo.2017.4221","article-title":"Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.","volume":"52","author":"Hira-Miyazawa","year":"2018","journal-title":"Int. J. Oncol."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-019-1358-y","article-title":"The functions and clinical application potential of exosomes derived from adipose mesenchymal stem cells: a comprehensive review.","volume":"10","author":"Hong","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"B90","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1158\/0008-5472.CAN-10-4455","article-title":"Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis.","volume":"71","author":"Hood","year":"2011","journal-title":"Cancer Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade.","volume":"128","author":"Hsu","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B92","doi-asserted-by":"publisher","first-page":"4800","DOI":"10.1002\/anie.201916039","article-title":"Homogeneous, low-volume, efficient, and sensitive quantitation of circulating exosomal PD-L1 for cancer diagnosis and immunotherapy response prediction.","volume":"59","author":"Huang","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"B93","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-3-319-74470-4_7","article-title":"Exosomes function in tumor immune microenvironment.","volume":"1056","author":"Huang","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"B95","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/ncb2530","article-title":"Get on the exosome bus with ALIX.","volume":"14","author":"Hurley","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape.","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol. Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum. Vaccin Immunother."},{"key":"B98","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.bbcan.2018.11.006","article-title":"What is the blood concentration of extracellular vesicles? Implications for the use of extracellular vesicles as blood-borne biomarkers of cancer.","volume":"1871","author":"Johnsen","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"B99","doi-asserted-by":"publisher","first-page":"25965","DOI":"10.1074\/jbc.M116.741884","article-title":"Identification of Neutrophil Exocytosis Inhibitors (Nexinhibs), Small Molecule Inhibitors of Neutrophil Exocytosis and Inflammation: druggability of the small GTPase Rab27a.","volume":"291","author":"Johnson","year":"2016","journal-title":"J. Biol. Chem."},{"key":"B100","first-page":"1","article-title":"Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy.","volume":"10","author":"Ju","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"B101","doi-asserted-by":"publisher","first-page":"6054","DOI":"10.1158\/1078-0432.CCR-16-1688","article-title":"PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors.","volume":"23","author":"Kakavand","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1172\/JCI81135","article-title":"The biology and function of exosomes in cancer.","volume":"126","author":"Kalluri","year":"2016","journal-title":"J. Clin. Invest."},{"key":"B103","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1073\/pnas.1705327114","article-title":"Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.","volume":"114","author":"Kamphorst","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B104","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1158\/0008-5472.CAN-15-0748","article-title":"PD-1 blunts the function of ovarian tumor-infiltrating dendritic cells by inactivating NF-kappaB.","volume":"76","author":"Karyampudi","year":"2016","journal-title":"Cancer Res."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/labinvest.2017.64","article-title":"Melanoma subtypes demonstrate distinct PD-L1 expression profiles.","volume":"97","author":"Kaunitz","year":"2017","journal-title":"Lab. Invest."},{"key":"B106","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/SHK.0000000000001228","article-title":"Integrin and PD-1 ligand expression on circulating extracellular vesicles in systemic inflammatory response syndrome and sepsis.","volume":"52","author":"Kawamoto","year":"2019","journal-title":"Shock"},{"key":"B107","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1097\/MPA.0000000000000847","article-title":"Exosomal Markers (CD63 and CD9) expression pattern using immunohistochemistry in resected malignant and nonmalignant pancreatic specimens.","volume":"46","author":"Khushman","year":"2017","journal-title":"Pancreas"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0295-2","article-title":"Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer.","volume":"51","author":"Kim","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080809","article-title":"Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC.","volume":"8","author":"Kloten","year":"2019","journal-title":"Cells"},{"key":"B110","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ceb.2014.05.004","article-title":"Biogenesis and secretion of exosomes.","volume":"29","author":"Kowal","year":"2014","journal-title":"Curr. Opin. Cell Biol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"E10119","DOI":"10.1073\/pnas.1802166115","article-title":"Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).","volume":"115","author":"Kowanetz","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B112","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/jclinpath-2017-204853","article-title":"Pd-L1.","volume":"71","author":"Kythreotou","year":"2018","journal-title":"J. Clin. Pathol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1161\/ATVBAHA.118.311208","article-title":"nSMase2 (Type 2-Neutral Sphingomyelinase) Deficiency or Inhibition by GW4869 Reduces Inflammation and Atherosclerosis in Apoe(-\/-) Mice.","volume":"38","author":"Lallemand","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/0008-5472.CAN-18-0014","article-title":"M2 macrophage-derived exosomes promote cell migration and invasion in colon cancer.","volume":"79","author":"Lan","year":"2019","journal-title":"Cancer Res."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-019-0376-6","article-title":"PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.","volume":"39","author":"Larsen","year":"2019","journal-title":"Cancer Commun."},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1177\/1534735419848047","article-title":"Breast tumor cells highly resistant to drugs are controlled only by the immune response induced in an immunocompetent mouse model.","volume":"18","author":"Lasso","year":"2019","journal-title":"Integr. Cancer Ther."},{"key":"B117","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation.","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat. Immunol."},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2019.1656993","article-title":"DNA analysis of low- and high-density fractions defines heterogeneous subpopulations of small extracellular vesicles based on their DNA cargo and topology.","volume":"8","author":"Lazaro-Ibanez","year":"2019","journal-title":"J. Extracell. Vesicles"},{"key":"B119","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ccell.2019.06.008","article-title":"Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1\/PD-L1 Therapeutic Efficacy.","volume":"36","author":"Lee","year":"2019","journal-title":"Cancer Cell"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-2101-2","article-title":"Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.","volume":"17","author":"Li","year":"","journal-title":"J. Transl. Med."},{"key":"B121","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","article-title":"Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma.","volume":"176","author":"Li","year":"","journal-title":"Cell"},{"key":"B122","doi-asserted-by":"publisher","first-page":"429","DOI":"10.21037\/tlcr.2019.08.04","article-title":"The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients.","volume":"8","author":"Li","year":"","journal-title":"Transl. Lung Cancer Res."},{"key":"B123","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00262-017-2086-8","article-title":"Cross-talk between TNF-alpha and IFN-gamma signaling in induction of B7-H1 expression in hepatocellular carcinoma cells.","volume":"67","author":"Li","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00883","article-title":"Expression of programmed cell death-ligands in hepatocellular carcinoma: correlation with immune microenvironment and survival outcomes.","volume":"9","author":"Liao","year":"2019","journal-title":"Front. Oncol."},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1172\/JCI120803","article-title":"Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.","volume":"128","author":"Lin","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B126","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1080\/15384047.2019.1670520","article-title":"Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-gamma to evaluate the efficacy of PD-L1\/PD-1-targeted immunotherapy.","volume":"21","author":"Lin","year":"2020","journal-title":"Cancer Biol. Ther."},{"key":"B127","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1021\/acs.nanolett.8b01184","article-title":"Single-exosome-counting immunoassays for cancer diagnostics.","volume":"18","author":"Liu","year":"","journal-title":"Nano Lett."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1021\/acssensors.8b00230","article-title":"Sensitive detection of exosomal proteins via a compact surface plasmon resonance biosensor for cancer diagnosis.","volume":"3","author":"Liu","year":"","journal-title":"ACS Sens."},{"key":"B129","doi-asserted-by":"publisher","first-page":"10712","DOI":"10.1021\/acsnano.7b04878","article-title":"The exosome total isolation chip.","volume":"11","author":"Liu","year":"2017","journal-title":"ACS Nano"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00009","article-title":"The clinical significance of soluble programmed cell Death-Ligand 1 (sPD-L1) in patients with gliomas.","volume":"10","author":"Liu","year":"2020","journal-title":"Front. Oncol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"S308","DOI":"10.21037\/tlcr.2019.08.02","article-title":"Biomarker for personalized immunotherapy.","volume":"8","author":"Liu","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920940927","article-title":"Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis.","volume":"12","author":"Liu","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0647-8","article-title":"Abscopal effect of radiotherapy combined with immune checkpoint inhibitors.","volume":"11","author":"Liu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ceb.2015.04.013","article-title":"Extracellular vesicles shuffling intercellular messages: for good or for bad.","volume":"35","author":"Lo Cicero","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3402\/jev.v4.27031","article-title":"Optimized exosome isolation protocol for cell culture supernatant and human plasma.","volume":"4","author":"Lobb","year":"2015","journal-title":"J. Extracell. Vesicles"},{"key":"B136","doi-asserted-by":"publisher","first-page":"41128","DOI":"10.1074\/jbc.M206747200","article-title":"Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase.","volume":"277","author":"Luberto","year":"2002","journal-title":"J. Biol. Chem."},{"key":"B137","doi-asserted-by":"publisher","first-page":"E98","DOI":"10.1093\/neuros\/nyy295","article-title":"Extracellular vesicles containing PD-L1 contribute to immune evasion in glioblastoma.","volume":"83","author":"Lubin","year":"2018","journal-title":"Neurosurgery"},{"key":"B138","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-16-2819","article-title":"Suppression of lymphocyte functions by plasma exosomes correlates with disease activity in patients with head and neck cancer.","volume":"23","author":"Ludwig","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133305","article-title":"c-Met and PD-L1 on circulating exosomes as diagnostic and prognostic markers for pancreatic cancer.","volume":"20","author":"Lux","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B140","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/pcmr.12340","article-title":"PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1\/PD-L1 clinical trials.","volume":"28","author":"Madore","year":"2015","journal-title":"Pigment Cell Melanoma Res."},{"key":"B141","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma.","volume":"37","author":"Mahoney","year":"2015","journal-title":"Clin. Ther."},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000363","article-title":"The biology of extracellular vesicles: the known unknowns.","volume":"17","author":"Margolis","year":"2019","journal-title":"PLoS Biol."},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1557030","article-title":"PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression.","volume":"8","author":"Mariotti","year":"2019","journal-title":"Oncoimmunology"},{"key":"B144","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41374-019-0295-9","article-title":"Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray.","volume":"100","author":"Martinez-Morilla","year":"2020","journal-title":"Lab. Invest."},{"key":"B145","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cell.2017.06.047","article-title":"Unshielding exosomal RNA unleashes tumor growth and metastasis.","volume":"170","author":"Matei","year":"2017","journal-title":"Cell"},{"key":"B146","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature13847","article-title":"The ESCRT machinery regulates the secretion and long-range activity of Hedgehog.","volume":"516","author":"Matusek","year":"2014","journal-title":"Nature"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0269-7","article-title":"Tumor-derived exosomes induce CD8(+) T cell suppressors.","volume":"5","author":"Maybruck","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav7431","article-title":"Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.","volume":"12","author":"Mayoux","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"B149","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jconrel.2015.06.029","article-title":"Exosome mediated communication within the tumor microenvironment.","volume":"219","author":"Milane","year":"2015","journal-title":"J. Control. Release"},{"key":"B150","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade.","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/cas.13424","article-title":"PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer.","volume":"109","author":"Mimura","year":"2018","journal-title":"Cancer Sci."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1515\/hsz-2013-0141","article-title":"Current methods for the isolation of extracellular vesicles.","volume":"394","author":"Momen-Heravi","year":"2013","journal-title":"Biol. Chem."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/1878-0261.12658","article-title":"Radiotherapy-immunotherapy combinations - perspectives and challenges.","volume":"14","author":"Mondini","year":"2020","journal-title":"Mol. Oncol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.celrep.2018.06.066","article-title":"ALIX regulates tumor-mediated immunosuppression by controlling EGFR activity and PD-L1 presentation.","volume":"24","author":"Monypenny","year":"2018","journal-title":"Cell Rep."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1074\/mcp.RA117.000037","article-title":"Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma.","volume":"16","author":"Morales-Betanzos","year":"2017","journal-title":"Mol. Cell Proteomics"},{"key":"B156","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3747\/co.25.4235","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a brief review.","volume":"25","author":"Myers","year":"2018","journal-title":"Curr. Oncol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s10147-018-1259-6","article-title":"Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.","volume":"23","author":"Nagai","year":"2018","journal-title":"Int. J. Clin. Oncol."},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-020-01079-z","article-title":"Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer.","author":"Nakayama","year":"2020","journal-title":"Gastric Cancer."},{"key":"B159","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/neuonc\/nov172","article-title":"PD-L1 expression and prognostic impact in glioblastoma.","volume":"18","author":"Nduom","year":"2016","journal-title":"Neuro Oncol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/ni.3466","article-title":"Immunometabolism of regulatory T cells.","volume":"17","author":"Newton","year":"2016","journal-title":"Nat. Immunol."},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.50256","article-title":"Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist.","volume":"8","author":"Ng","year":"2019","journal-title":"eLife"},{"key":"B162","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect.","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"B163","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-13-0895","article-title":"Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements.","volume":"19","author":"Nishino","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2016.11.023","article-title":"High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.","volume":"104","author":"Okuma","year":"2017","journal-title":"Lung Cancer"},{"key":"B165","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ceb.2015.12.001","article-title":"The ESCRT machinery: new roles at new holes.","volume":"38","author":"Olmos","year":"2016","journal-title":"Curr. Opin. Cell Biol."},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1744980","article-title":"ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance.","volume":"9","author":"Orme","year":"2020","journal-title":"Oncoimmunology"},{"key":"B167","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ncb2000","article-title":"Rab27a and Rab27b control different steps of the exosome secretion pathway.","volume":"12","author":"Ostrowski","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-med-092012-112807","article-title":"Immune modulation in cancer with antibodies.","volume":"65","author":"Page","year":"2014","journal-title":"Annu. Rev. Med."},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2019.111800","article-title":"Personalized detection of circling exosomal PD-L1 based on Fe3O4@TiO2 isolation and SERS immunoassay.","volume":"148","author":"Pang","year":"2020","journal-title":"Biosens. Bioelectron."},{"key":"B170","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1182\/blood-2010-01-265975","article-title":"B7-H1\/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance.","volume":"116","author":"Park","year":"2010","journal-title":"Blood"},{"key":"B171","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.","volume":"25","author":"Parry","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy.","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2002796","article-title":"Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.","volume":"5","author":"Patsoukis","year":"2012","journal-title":"Sci. Signal."},{"key":"B174","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1111\/febs.12775","article-title":"Regulation of exosome release by glycosphingolipids and flotillins.","volume":"281","author":"Phuyal","year":"2014","journal-title":"FEBS J."},{"key":"B175","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","article-title":"Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory.","volume":"177","author":"Poggio","year":"2019","journal-title":"Cell"},{"key":"B176","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/j.yexcr.2008.09.020","article-title":"Trafficking and function of the tetraspanin CD63.","volume":"315","author":"Pols","year":"2009","journal-title":"Exp. Cell Res."},{"key":"B177","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma.","volume":"366","author":"Postow","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1002\/0471142735.im2002s39","article-title":"Mouse 4T1 breast tumor model.","author":"Pulaski","year":"2001","journal-title":"Curr. Protoc. Immunol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis.","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072286","article-title":"Extracellular vesicles and tumor-immune escape: biological functions and clinical perspectives.","volume":"21","author":"Raimondo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B181","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma.","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"key":"B182","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1084\/jem.20161462","article-title":"What does PD-L1 positive or negative mean?","volume":"213","author":"Ribas","year":"2016","journal-title":"J. Exp. Med."},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aar2766","article-title":"Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles.","volume":"4","author":"Ricklefs","year":"2018","journal-title":"Sci. Adv."},{"key":"B184","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00767.x","article-title":"PD-1 signaling in primary T cells.","volume":"229","author":"Riley","year":"2009","journal-title":"Immunol. Rev."},{"key":"B185","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.it.2018.06.001","article-title":"Immunological mechanisms responsible for radiation-induced abscopal effect.","volume":"39","author":"Rodriguez-Ruiz","year":"2018","journal-title":"Trends Immunol."},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7659462","article-title":"CD80 Expressed by CD8(+) T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8(+) T Cells.","volume":"2017","author":"Rollins","year":"2017","journal-title":"J. Immunol. Res."},{"key":"B187","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00262-019-02437-2","article-title":"Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells.","volume":"69","author":"Romero","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"B188","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1002\/eji.200939407","article-title":"B7-1\/2, but not PD-L1\/2 molecules, are required on IL-10-treated tolerogenic DC and DC-derived exosomes for in vivo function.","volume":"39","author":"Ruffner","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"6480","DOI":"10.1158\/0008-5472.CAN-17-0994","article-title":"The biology of cancer exosomes: insights and new perspectives.","volume":"77","author":"Ruivo","year":"2017","journal-title":"Cancer Res."},{"key":"B190","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/jcb.29120","article-title":"Exosomes: new insights into cancer mechanisms.","volume":"121","author":"Sahebi","year":"2020","journal-title":"J. Cell. Biochem."},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-018-0770-0","article-title":"Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.","volume":"20","author":"Sandigursky","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"B192","doi-asserted-by":"publisher","first-page":"R116","DOI":"10.1016\/j.cub.2012.01.028","article-title":"The ESCRT machinery.","volume":"22","author":"Schmidt","year":"2012","journal-title":"Curr. Biol."},{"key":"B193","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrm.2016.121","article-title":"Reverse-topology membrane scission by the ESCRT proteins.","volume":"18","author":"Schoneberg","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B194","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1111\/cas.13735","article-title":"Exosome-mediated regulation of tumor immunology.","volume":"109","author":"Seo","year":"2018","journal-title":"Cancer Sci."},{"key":"B195","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy.","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.235085","article-title":"Tumor-derived extracellular vesicles: molecular parcels that enable regulation of the immune response in cancer.","volume":"132","author":"Sheehan","year":"2019","journal-title":"J. Cell Sci."},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3529","article-title":"Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis.","volume":"362","author":"Shen","year":"2018","journal-title":"BMJ"},{"key":"B198","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","article-title":"PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3zeta signalosome and downstream signaling to PKCtheta.","volume":"574","author":"Sheppard","year":"2004","journal-title":"FEBS Lett."},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104258","article-title":"Understanding and overcoming the resistance of cancer to PD-1\/PD-L1 blockade.","volume":"145","author":"Shergold","year":"2019","journal-title":"Pharmacol. Res."},{"key":"B200","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1245\/s10434-018-07112-x","article-title":"Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.","volume":"26","author":"Shigemori","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"B201","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.jtho.2016.02.015","article-title":"Predictive markers for the efficacy of Anti-PD-1\/PD-L1 antibodies in lung cancer.","volume":"11","author":"Shukuya","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"B202","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors : skin toxicities and immunotherapy.","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/ncb1800","article-title":"Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.","volume":"10","author":"Skog","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar5078","article-title":"Triggered recruitment of ESCRT machinery promotes endolysosomal repair.","volume":"360","author":"Skowyra","year":"2018","journal-title":"Science"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100811","article-title":"Programmed Cell Death-Ligand 2: a neglected but important target in the immune response to cancer?","volume":"13","author":"Solinas","year":"2020","journal-title":"Transl. Oncol."},{"key":"B206","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"B207","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/cr.2015.39","article-title":"Resolving sorting mechanisms into exosomes.","volume":"25","author":"Stoorvogel","year":"2015","journal-title":"Cell Res."},{"key":"B208","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10549-019-05130-1","article-title":"PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review.","volume":"174","author":"Stovgaard","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"B209","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1126\/science.aav7062","article-title":"Restriction of PD-1 function by cis-PD-L1\/CD80 interactions is required for optimal T cell responses.","volume":"364","author":"Sugiura","year":"2019","journal-title":"Science"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6984948","article-title":"Anti-PD-1\/PD-L1 Therapy for Non-Small-Cell Lung Cancer: toward Personalized Medicine and Combination Strategies.","volume":"2018","author":"Sui","year":"2018","journal-title":"J. Immunol. Res."},{"key":"B211","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and Function of the PD-L1 Checkpoint.","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"B212","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1158\/1078-0432.CCR-16-1821","article-title":"PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison.","volume":"23","author":"Sunshine","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B213","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semcdb.2017.08.012","article-title":"Endosomal \u201csort\u201d of signaling control: the role of ESCRT machinery in regulation of receptor-mediated signaling pathways.","volume":"74","author":"Szymanska","year":"2018","journal-title":"Semin. Cell Dev. Biol."},{"key":"B214","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.imlet.2018.01.007","article-title":"Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.","volume":"196","author":"Takeuchi","year":"2018","journal-title":"Immunol. Lett."},{"key":"B215","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1158\/1078-0432.CCR-18-3991","article-title":"Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity.","volume":"25","author":"Tanegashima","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B216","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1172\/JCI96061","article-title":"PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.","volume":"128","author":"Tang","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B217","doi-asserted-by":"publisher","first-page":"24500","DOI":"10.1073\/pnas.1916916116","article-title":"A high-affinity human PD-1\/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery.","volume":"116","author":"Tang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00604","article-title":"The biogenesis, biology, and clinical significance of exosomal PD-L1 in cancer.","volume":"11","author":"Tang","year":"2020","journal-title":"Front. Immunol."},{"key":"B219","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.","volume":"20","author":"Taube","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918763493","article-title":"PD-L1 expression testing in non-small cell lung cancer.","volume":"10","author":"Teixido","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B221","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/cei.13113","article-title":"Separation of plasma-derived exosomes into CD3((+) and CD3((-) fractions allows for association of immune cell and tumour cell markers with disease activity in HNSCC patients.","volume":"192","author":"Theodoraki","year":"","journal-title":"Clin. Exp. Immunol."},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1593805","article-title":"Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT.","volume":"8","author":"Theodoraki","year":"2019","journal-title":"Oncoimmunology"},{"key":"B223","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1158\/1078-0432.CCR-17-2664","article-title":"Clinical significance of PD-L1(+) exosomes in plasma of head and neck cancer patients.","volume":"24","author":"Theodoraki","year":"","journal-title":"Clin. Cancer Res."},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1002\/0471143030.cb0322s30","article-title":"Isolation and characterization of exosomes from cell culture supernatants and biological fluids.","author":"Thery","year":"2006","journal-title":"Curr. Protoc. Cell Biol."},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2016.0479","article-title":"Why the need and how to approach the functional diversity of extracellular vesicles.","volume":"373","author":"Tkach","year":"2018","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"B226","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.cell.2016.01.043","article-title":"Communication by extracellular vesicles: Where we are and where we need to go.","volume":"164","author":"Tkach","year":"2016","journal-title":"Cell"},{"key":"B227","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1126\/science.1153124","article-title":"Ceramide triggers budding of exosome vesicles into multivesicular endosomes.","volume":"319","author":"Trajkovic","year":"2008","journal-title":"Science"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13582","article-title":"Pembrolizumab-induced pancytopenia in a patient with squamous cell lung cancer.","author":"Ueki","year":"2020","journal-title":"Thorac. Cancer."},{"key":"B229","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrm.2017.125","article-title":"Shedding light on the cell biology of extracellular vesicles.","volume":"19","author":"van Niel","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B230","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2174\/0929867324666170407125017","article-title":"Immune checkpoint inhibitors and cardiac toxicity: an emerging issue.","volume":"25","author":"Varricchi","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"B231","doi-asserted-by":"publisher","first-page":"8844","DOI":"10.4049\/jimmunol.177.12.8844","article-title":"Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis.","volume":"177","author":"Wan","year":"2006","journal-title":"J. Immunol."},{"key":"B232","first-page":"1661","article-title":"Exosome-mediated cell-cell communication in tumor progression.","volume":"8","author":"Wan","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"B233","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","article-title":"Adverse renal effects of immune checkpoint inhibitors: a narrative review.","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006369","article-title":"Prognostic significance of PD-L1 in solid tumor: an updated meta-analysis.","volume":"96","author":"Wang","year":"2017","journal-title":"Medicine"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0810-y","article-title":"Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients.","volume":"7","author":"Wang","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4197829","article-title":"Functions of exosomes in the triangular relationship between the tumor, inflammation, and immunity in the tumor microenvironment.","volume":"2019","author":"Wang","year":"2019","journal-title":"J. Immunol. Res."},{"key":"B237","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.molimm.2019.02.009","article-title":"PD-1-expressing B cells suppress CD4(+) and CD8(+) T cells via PD-1\/PD-L1-dependent pathway.","volume":"109","author":"Wang","year":"2019","journal-title":"Mol. Immunol."},{"key":"B238","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.imlet.2017.02.006","article-title":"Inflammatory cytokines IL-17 and TNF-alpha up-regulate PD-L1 expression in human prostate and colon cancer cells.","volume":"184","author":"Wang","year":"2017","journal-title":"Immunol. Lett."},{"key":"B239","doi-asserted-by":"publisher","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1804362","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management.","author":"Williams","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B241","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor.","volume":"20","author":"Wolf","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.07.031","article-title":"High expression of PD-L1 and PD-L2 in ophthalmic sebaceous carcinoma: the case for a clinical trial of checkpoint inhibitors.","author":"Wolkow","year":"2020","journal-title":"Am. J. Ophthalmol."},{"key":"B243","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.devcel.2019.04.011","article-title":"Exosome-mediated metastasis: communication from a distance.","volume":"49","author":"Wortzel","year":"2019","journal-title":"Dev. Cell"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-0366-x","article-title":"Small molecule inhibitors targeting the PD-1\/PD-L1 signaling pathway.","author":"Wu","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01719","article-title":"T cell dysfunction in cancer immunity and immunotherapy.","volume":"10","author":"Xia","year":"2019","journal-title":"Front. Immunol."},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0985-3","article-title":"The role of extracellular vesicles from different origin in the microenvironment of head and neck cancers.","volume":"18","author":"Xie","year":"2019","journal-title":"Mol. Cancer"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1074-3","article-title":"The role of exosomal PD-L1 in tumor progression and immunotherapy.","volume":"18","author":"Xie","year":"2019","journal-title":"Mol. Cancer"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00897","article-title":"The clinicopathological and prognostic value of PD-L1 expression in cholangiocarcinoma: a meta-analysis.","volume":"9","author":"Xu","year":"2019","journal-title":"Front. Oncol."},{"key":"B249","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1172\/JCI81129","article-title":"Extracellular vesicle isolation and characterization: toward clinical application.","volume":"126","author":"Xu","year":"2016","journal-title":"J. Clin. Invest."},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.10.093","article-title":"A tumor-specific super-enhancer drives immune evasion by guiding synchronous expression of PD-L1 and PD-L2.","volume":"29","author":"Xu","year":"2019","journal-title":"Cell Rep."},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01597","article-title":"PD-1\/PD-L1 blockade: Have we found the key to unleash the antitumor immune response?","volume":"8","author":"Xu-Monette","year":"2017","journal-title":"Front. Immunol."},{"key":"B252","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.biopha.2018.11.105","article-title":"PD-1\/PD-L1 blockade as a novel treatment for colorectal cancer.","volume":"110","author":"Yaghoubi","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.3402\/jev.v4.27066","article-title":"Biological properties of extracellular vesicles and their physiological functions.","volume":"4","author":"Yanez-Mo","year":"2015","journal-title":"J. Extracell. Vesicles"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201600699","article-title":"Exosome separation using microfluidic systems: size-based, immunoaffinity-based and dynamic methodologies.","volume":"12","author":"Yang","year":"2017","journal-title":"Biotechnol. J."},{"key":"B255","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41422-018-0060-4","article-title":"Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth.","volume":"28","author":"Yang","year":"2018","journal-title":"Cell Res."},{"key":"B256","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41551-019-0485-1","article-title":"Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation.","volume":"4","author":"Yang","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"B257","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","article-title":"PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer.","volume":"23","author":"Yearley","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2019.1689784","article-title":"Large and small extracellular vesicles released by glioma cells in vitro and in vivo.","volume":"9","author":"Yekula","year":"2020","journal-title":"J. Extracell. Vesicles"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03137","article-title":"Extracellular vesicles in glioblastoma tumor microenvironment.","volume":"10","author":"Yekula","year":"2019","journal-title":"Front. Immunol."},{"key":"B260","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J. Exp. Med."},{"key":"B261","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/s0006-291x(03)01257-9","article-title":"Differential binding properties of B7-H1 and B7-DC to programmed death-1.","volume":"307","author":"Youngnak","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B262","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jtho.2016.04.014","article-title":"PD-L1 expression in lung cancer.","volume":"11","author":"Yu","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"B263","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1038\/s41388-018-0303-3","article-title":"Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.","volume":"37","author":"Zerdes","year":"2018","journal-title":"Oncogene"},{"key":"B264","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.bbcan.2019.04.004","article-title":"Exosomes in cancer development, metastasis, and immunity.","volume":"1871","author":"Zhang","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-019-0282-2","article-title":"Exosomes: biogenesis, biologic function and clinical potential.","volume":"9","author":"Zhang","year":"2019","journal-title":"Cell Biosci."},{"key":"B266","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.immuni.2019.11.003","article-title":"PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.","volume":"51","author":"Zhao","year":"2019","journal-title":"Immunity"},{"key":"B267","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1039\/c8lc01123k","article-title":"Extracellular vesicles as cancer liquid biopsies: from discovery, validation, to clinical application.","volume":"19","author":"Zhao","year":"2019","journal-title":"Lab Chip"},{"key":"B268","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1158\/2326-6066.CIR-16-0329","article-title":"Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade.","volume":"5","author":"Zhou","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"B269","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1089\/scd.2018.0033","article-title":"Immunosuppression of human adipose-derived stem cells on t cell subsets via the reduction of NF-kappaB activation mediated by PD-L1\/PD-1 and Gal-9\/TIM-3 Pathways.","volume":"27","author":"Zhou","year":"2018","journal-title":"Stem Cells Dev."},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations.","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.569219\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T05:05:43Z","timestamp":1602738343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.569219\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":270,"alternative-id":["10.3389\/fcell.2020.569219"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2020.569219","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"article-number":"569219"}}